No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1624.5x · 10Y median 1613.0x · 54th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 17
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:03:33.450Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Oculis Holding AG (OCS) stock was $8.67 as of Oct 6, 2026, 1:00 PM EDT, up 1.27% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -51.1% · 3-year avg -9.0%/yr · 5-year avg -2.4%/yr
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema.
Biotechnology · Zug, ZG
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.49
Revenue Est.
$259095.00
Last Quarter Results
EPS
$-0.16
vs Estimate
$-0.38
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OCS | $495.60M | $8.67 | +1.27% | -51.11% | -2.41% | N/A | N/A |
| 2EOLS | $490.41M | $7.45 | -0.31% | +14.85% | +0.46% | N/A | vs OCS |
| 3PBYI | $486.60M | $9.56 | -1.14% | +87.93% | +9.26% | -17.43% | vs OCS |
| 4ALLO | $509.10M | $1.48 | -1.67% | +12.72% | -42.72% | N/A | vs OCS |
| 5MASS | $509.56M | $12.42 | -2.97% | +40.89% | -17.66% | N/A | vs OCS |
| 6CBIO | $509.80M | $13.72 | -1.54% | +18.84% | -24.40% | -22.94% | vs OCS |
N/A
$383501.00
vs Estimate
$216839.00
Consensus Rating
Based on 10 analysts
Average Price Target
$36.53
+321.4% upside
Low
$19.53
Current
$8.67
High
$43.69
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | CHF -0.43 | CHF -0.40 | CHF -0.38 | 6 |
| Quarter ending Dec 2026 | CHF -0.45 | CHF -0.43 | CHF -0.41 | 5 |
| Quarter ending Mar 2027 | CHF -0.62 | CHF -0.39 | CHF -0.28 | 3 |
| Quarter ending Jun 2027 | CHF -0.62 | CHF -0.39 | CHF -0.28 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | CHF -2.02 | CHF -1.56 | CHF -1.36 | 6 |
| FY 2027 | CHF -2.01 | CHF -1.72 | CHF -1.37 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | CHF 179644.00 | CHF 215573.00 | CHF 273059.00 | 6 |
| Quarter ending Dec 2026 | CHF 165423.00 | CHF 211742.00 | CHF 304379.00 | 6 |
| Quarter ending Mar 2027 | CHF 78398.00 | CHF 100350.00 | CHF 144253.00 | 3 |
| Quarter ending Jun 2027 | CHF 78398.00 | CHF 100350.00 | CHF 144253.00 | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | CHF 782776.00 | CHF 865174.00 | CHF 1.02M | 7 |
| FY 2027 | CHF 1.11M | CHF 4.12M | CHF 9.56M | 7 |
